BRAF V600E
Identifier: NCT01336634 - ClinicalTrials.gov Study Information
This clinical trial is designed for patients whose tumors have a specific genetic change, or mutation, in the BRAF gene, which results in a change at the 600th site of the B-Raf protein (V600E), the mutation causes the protein to be inappropriately “turned on”, telling cancer cells to multiply.
Title
A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF Mutations
Eligibility
Patients with non-small cell lung cancer who have been previously treated with one or more therapies, and have the V600E BRAF mutation in their tumor, are eligible for this study.
Treatment
All study participants will receive GSK2118436 (dabrafenib).
About dabrafenib
Dabrafenib is an inhibitor of the B-raf protein, preventing B-raf from using the cell’s energy stores for fuel. This causes a “block” to the activity of B-raf (which is inappropriately “turned on” when its gene is mutated) and kills the cancer cell.
back to clinical trials listing
This clinical trial is designed for patients whose tumors have a specific genetic change, or mutation, in the BRAF gene, which results in a change at the 600th site of the B-Raf protein (V600E), the mutation causes the protein to be inappropriately “turned on”, telling cancer cells to multiply.
Title
A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF Mutations
Eligibility
Patients with non-small cell lung cancer who have been previously treated with one or more therapies, and have the V600E BRAF mutation in their tumor, are eligible for this study.
Treatment
All study participants will receive GSK2118436 (dabrafenib).
About dabrafenib
Dabrafenib is an inhibitor of the B-raf protein, preventing B-raf from using the cell’s energy stores for fuel. This causes a “block” to the activity of B-raf (which is inappropriately “turned on” when its gene is mutated) and kills the cancer cell.
back to clinical trials listing
